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involved in membrane binding, vesicle trafficking and lipid biogenesis (Table S1 ; Data set 1). 140 141
GFP-tagging of proteins confirms their Maurer's cleft location 142
To determine or confirm the locations of a number of the identified proteins, we generated 143 transfectants expressing GFP fusions of five uncharacterised or partially characterised proteins 144 (VCAP1, GEXP10/CBP1, PTP5, PTP6 and PF3D7_1353100) and two proteins that were 145 previously reported to be Maurer's cleft-located (REX1 (17) and MAHRP1), each under the control 146 of the CRT (chloroquine resistance transporter) promoter (Fig 2) . An immunoblot probed with anti-147 GFP confirms the expression of chimeric proteins that migrate close to the calculated molecular 148 masses ( Fig S1C) . Using live-cell microscopy, we showed that each of the GFP-tagged proteins 149 localises to puncta in the host RBC cytoplasm, consistent with Maurer's cleft association (Fig 2) . 150
Immunofluorescence microscopy of samples co-labelled with antibodies recognising GFP and 151 REX1 confirmed that the proteins are directed to the Maurer's clefts ( Fig S2A) . A previous study 152 suggested that VCAP1 and GEXP10 are present at the RBC surface (29) . While the presence of a 153 7 small sub-population at the RBC surface or in the RBC cytoplasm cannot be ruled out, our 154 immunofluorescence microscopy shows that the bulk of the protein is located at the Maurer's clefts 155 (Fig 2; Fig S2A) . 156 157 Co-IP of Maurer's cleft proteins reveals a compartmentalised network of protein interaction 158 clusters 159
We performed co-IP experiments on our GFP-tagged transfectants. Western analysis confirmed the 160 enrichment of the GFP-tagged bait proteins (Fig S2B-D) . In each of the lines analysed the bait 161 protein and several interacting proteins were identified (Table S2-8; Data sets 2-8). The protein 162 interaction networks were analysed using Navigator ( Fig 3A,B, S3 ) (34) . When combined with data 163 from other studies that performed IPs with epitope-tagged PTP1, SEMP1 and PfEMP1, a complex 164 map of interactions is revealed ( Fig S3B) (15, 16, 31) . We identified 2 protein clusters that each 165 contains Maurer's cleft proteins that are known to have roles in PfEMP1 trafficking, connecting to 166 uncharacterised proteins and to PfEMP1 itself (Fig 3A, B) . 167
For example, previous work showed that MAHRP1 is needed for efficient loading of PfEMP1 into 168 the Maurer's clefts (35) . We found that MAHRP1-GFP co-precipitated VCAP1 and GEXP10, while 169 VCAP1-GFP and GEXP10-GFP co-precipitated MAHRP1 (Table S2-4; Data sets 2-4). These 170 interactions were confirmed by Western blotting (Fig S2E) . GEXP10-GFP and MAHRP1-GFP also 171 precipitated PIESP2, while VCAP1-GFP precipitated Pf322, consistent with its known Maurer's 172 cleft location. VCAP1-GFP and GEXP10-GFP also precipitated PfEMP1 (Table S2 -4; Data sets 2-173 4), suggesting a potential role for these proteins in PfEMP1 trafficking. 174 3D-Structured Illumination Microscopy (3D-SIM) provides an 8-fold increase in volume resolution, 175 which enhances the analysis of compartments, such as the Maurer's clefts, that have dimensions 176 close to the resolution limit of conventional microscopy. 3D-SIM reveals that REX1 is located 177 around the perimeter of the clefts, while MAHRP1 exhibits a more central location (Fig 3C, S4A) , 178 in agreement with our previous report (11). VCAP1-GFP and GEXP10-GFP are concentrated in the 179 8 central region of the Maurer's cleft surrounded by REX1 ( Fig 3D,E, S4B ). The profile for 180 antibodies recognising the ATS region of PfEMP1 exhibits partial overlap with that for GEXP10-181 GFP (Fig S4C) . 182
The interaction analysis revealed a second protein cluster containing REX1-GFP, PTP5-GFP and 183 PF3D7_1353100 (Fig 3B) . REX1-GFP co-precipitated PfEMP1 (Table S5 ; Data set 5), consistent 184 with the known role for REX1 in trafficking PfEMP1 from the Maurer's clefts to the RBC 185 membrane (36, 37) . A co-IP with PTP5-GFP co-precipitates REX1, PIESP2 and PfJ23 (Table S6 ; 186 Data sets 6). These data point to the existence of a protein interaction network comprised of 187 PfEMP1, REX1, PTP5 and PIESP2, potentially functioning at the cleft periphery ( Fig 3B) . GFP and PF3D7_1353100-GFP also co-precipitated the tether protein, MAHRP2 (Table S7 ; Data 189 set 7). 190 3D-SIM imaging of PTP5-GFP and PF3D7_1353100-GFP cell lines reveals a dotted pattern at the 191 periphery of the Maurer's cleft cisternae, partially overlapping or alternating with the REX1 signal 192 ( Fig 3F, G, S4B ). Similarly, PfEMP1 (ATS labelling) partly overlaps with REX1 and PfEMP1 at 193 the cleft periphery ( Fig S4C) . 194
Components of the PVM translocation machinery were observed in IPs with VCAP1-GFP 195 (HSP101, PTEX150), suggesting interactions with these proteins during the export processes. IPs 196 with PTP6-GFP showed a number of interacting proteins including MESA, STARP and three 197 proteins of unknown function, PF3D7_0702500, PF3D7_1002000 and PF3D7_0301700. This 198 protein interaction network showed no connectivity to the clusters described above (Table S8; As we were interested in identifying proteins that may be involved in trafficking PfEMP1, we 204 selected VCAP1 and GEXP10 (which IP each other and PfEMP1) as candidates for genetic 205 9 disruption. These genes have been previously reported to be refractory to deletion using 206 conventional approaches (21, 28) . In this work, we used a CRISPR-Cas9 approach to disrupt these 207 genes in CS2 parasites ( Fig S5) . We were unable to obtain a knockout of GEXP10 from two 208 separate attempts, supporting a recent genome-wide transposon screen which suggested that 209 GEXP10 is essential (38). By contrast, a knockout was obtained for VCAP1, with disruption of the 210 native locus confirmed by PCR ( Fig S5) . 211
We examined the VCAP1 infected RBCs by immunofluorescence microscopy, using antibodies to 212 REX1 and KAHRP ( Fig 4A) . An increase in the number of REX1-positive puncta was observed 213 suggesting a change in Maurer's cleft morphology ( Fig 4A) . The labelling pattern for KAHRP also 214 appeared more punctate ( Fig 4A) . We next analysed the growth of the VCAP1 parasite line 215 compared with the CS2 parent parasites. The VCAP1 parasite line grows faster than the parent 216 line with a more than 2-fold difference observed after four parasite cycles ( Fig 4B) . 217 218
Knockout of VCAP1 results in altered Maurer's cleft morphology 219
RBCs infected with the VCAP1 parasite line were lightly fixed and permeabilised with the pore-220 forming toxin, Equinatoxin II (EqtII; (39, 40)) to release haemoglobin and to permit the 221 introduction of primary antibodies recognising REX1. 222
Transmission electron microscopy was performed on thin sections prepared from CS2 and 223 VCAP1 infected RBCs. The Maurer's clefts are observed as single slender cisternae with an 224 electron-lucent lumen and an electron-dense coat in the wild type CS2 (Fig 4C, S6A) . In VCAP1 225 infected RBCs, distorted and fragmented structures are observed ( Fig 4C, S6A) . These fragments 226 label with immunogold labelled anti-REX1 antibodies, confirming a Maurer's cleft origin (gold 227 arrows; Fig 4C) . The 3D architecture of the Maurer's cleft fragments was examined using electron 228 tomography ( Fig 4D) . The rendered images reveal the fragmented nature of the Maurer's clefts 229 when compared to wildtype CS2. Each separate cleft structure is rendered in a different pastel hue; 230 the RBC (red) and the tethers (magenta) are also displayed ( Fig 4D) . The morphology changes are 231 10 best appreciated in translations through the virtual sections of the tomogram and rotations of the 232 rendered models (Movie S2-3). 233 234 VCAP1 parasite infected RBCs have altered knob morphology 235 Scanning Electron Microscopy (SEM) of intact VCAP1 infected RBCs reveals enlarged knobs 236 with a highly aberrant morphology, as well as knob clusters ( Fig 5A) . RBCs infected with VCAP1 237 parasites have fewer knob structures (1.3 + 0.2 per m 2 ) than wildtype CS2 (5.5 + 1 per m 2 ) ( Fig  238   5B ). Thin section TEM confirmed the altered knob morphology ( Fig S6B) . 239
To investigate the architecture of the knobs in more detail we made use of a recently developed 240 method for imaging knobs at the cytoplasmic surface of infected RBCs (2). Infected RBCs were 241 tightly linked to lectin-coated slides and subjected to shearing. The remnant membrane discs were 242 fixed, dehydrated, gold-coated, and then imaged using high-resolution SEM. The spectrin-actin 243 network is evident as bright skeletal elements over dark patches of background membrane ( Fig 5C) . 244
The knobs appear as raised, dimpled disk-shaped structures that are closely integrated into the 245 skeletal meshwork (Fig 5C, arrows) . About 75% of the knobs were malformed in the VCAP1 246 infected RBCs, presenting as asymmetrical, enlarged and clustered knob structures ( Fig 5D, S7A) . 247
The knobs in the VCAP1 infected RBC membranes exhibit a larger average diameter (90 + 1 nm) 248 than CS2 wild type parent (80 + 1 nm), and a broader size distribution ( Fig 5E) . 249 250
Knockout of VCAP1 ablates PfEMP1 surface expression and binding to chondroitin sulphate-251
A 252
To determine if PfEMP1 trafficking was affected in the VCAP1 infected RBCs we performed 253 immunofluorescence microscopy using antibodies directed towards the conserved acidic terminal 254 segment (ATS) of PfEMP1. Wildtype CS2 infected RBCs exhibit characteristic localisation of 255
PfEMP1 at the Maurer's clefts, while PfEMP1 labelling is much weaker in the VCAP1 infected 256 RBCs (Fig 6A, S7B) . 257 11 We next examined if PfEMP1 is displayed at the surface of VCAP1 infected RBCs by using a 258 trypsin cleavage assay (8, 32) . In this assay whole infected RBCs are treated with trypsin (T) or 259 with trypsin plus inhibitor (i), before Triton X-100 solubilisation. Only the Triton-insoluble (RBC 260 membrane-embedded) PfEMP1 population survives the extraction process. In the protease-inhibited 261 CS2 control (i), RBC membrane-embedded full-length PfEMP1 is evident, with an apparent 262 molecular mass of ~270 kDa ( Fig 6B, top blue arrow) . It is evident that the pool of RBC 263 membrane-embedded PfEMP1 is decreased in the VCAP1 infected RBCs ( To further examine surface presentation of PfEMP1, we used a rabbit polyclonal serum that 272 recognises VAR2CSA on the surface of CS2 parasite-infected RBCs (41). A strong signal was 273 observed in CS2 parasites, which was reduced by 90% in the VCAP1 infected RBCs (Fig 6C) . 274
The CS2 parent line expresses a fixed PfEMP1 variant, VAR2CSA, which binds to chondroitin 275 sulphate-A. We investigated infected RBC binding to immobilised chondroitin sulphate-A under 276 physiologically relevant flow conditions. RBCs infected with VCAP1 parasites show a 95% lower 277 level of adhesion compared to the CS2 parent ( Fig 6D) . This provides further evidence that in the 278 absence of VCAP1, parasites are unable to traffic PfEMP1 to the RBC surface. 279 280
RBCs infected with VCAP1 parasites have increased deformability and fragility 281
We examined the ability of CS2 and VCAP1 infected RBCs to filter through a bed of beads 282 designed to mimic splenic fenestrations. RBCs infected with VCAP1 parasites synchronised to 20-283 12 24 h post invasion (the window during which knob assembly and host cell remodelling occurs (2)) 284 exhibited a 23% increase in the filterability of the parasites compared to CS2 controls ( Fig 6E) . 285
We next examined the sensitivity of infected RBCs to osmotic lysis. We found that VCAP1 286 infected RBCs are more sensitive to sorbitol-induced swelling than RBCs infected with wildtype 287 CS2 ( Fig 6F) . 288
289
Discussion 290
The suggestion that Maurer's clefts play a role in transporting virulence proteins from the parasite 291 to the RBC membrane was first put forward nearly 40 years ago (42), however our understanding of 292 the repertoire of cleft-associated proteins and their functions remains incomplete. A previous study 293 examined the proteins present in the ghost fraction of trophozoite stage-infected RBCs and 294 characterised two novel Maurer's clefts proteins (14). More recently, proteomics approaches have 295 been used to define the "exportomes" of both P. yoelii and P. berghei (43, 44) . In this study, we 296 built on this work and defined the composition of Maurer's cleft in P. falciparum during the late 297 ring stage of infection (14 -18 h post-invasion). During this time window PfEMP1 is trafficked to 298 Maurer's clefts and a sub-population is transferred to the RBC membrane (8). A technical 299 advantage of this time window is that the Maurer's clefts are still mobile in the RBC cytoplasm, 300 allowing separation from host and other parasite components. 301
Making use of a previously generated REX1-GFP tagged line (17), we used GFP-Trap to affinity 302 purify clefts released by hypotonic lysis. Mass spectrometry analysis identified enriched peptides 303 from 18 proteins. Of these, 11 were previously shown to be Maurer's cleft-located proteins, and 7 304 were potentially novel residents. 305
We also observed enrichment of host cell proteins in the Maurer's clefts. The most highly enriched 306 protein was Annexin A4, which is involved in vesicle aggregation and the formation of lipid rafts 307 (45). Other enriched human proteins include Annexin A11, which binds to the calcium sensor, 308 calcyclin (33, 46) and Copine-3 (a calcium-dependent phospholipid-binding protein), as well as 309 13 VPS28, TSG101 (a component of the ESCRT-I complex), syntaxin-7 (a SNARE component) and 310 VAC14 (a scaffold protein involved in phosphatidylinositol 3,5-bisphosphate synthesis). All of 311 these proteins are involved in membrane trafficking. It is possible these proteins play roles in 312
Maurer's cleft sculpting, vesicle formation or PfEMP1 trafficking. 313
We generated transfectants expressing GFP fusions of five putative Maurer's cleft proteins and two 314 known resident proteins. We confirmed that all of the tagged proteins were located at the Maurer's 315 clefts. The cell lines were then employed in an investigation of protein-protein interactions using 316 GFP-Trap IP and protein identification by mass spectrometry. This analysis identified a network of 317 interactions. We identified hubs where newly identified or poorly characterised Maurer's clefts 318 proteins participate in networks with known PfEMP1 trafficking proteins and importantly PfEMP1 319 itself. 320
For example, we identified a network involving PfEMP1, REX1, PTP5 and the tether protein 321 MAHRP2. This is consistent with previous evidence that PTP5 co-precipitates with GFP-tagged 322
PfEMP1 and that REX1 and PTP5 are needed for PfEMP1 trafficking to the RBC surface (21, 31, 323 37) . We confirmed the interaction between REX1 and PfEMP1, consistent with a previous study 324
showing that GFP-tagged PfEMP1 co-precipitates REX1 and vice versa (31). Our previous work 325 showed that REX1 plays a role in trafficking PfEMP1 from the clefts to the RBC membrane. Using 326 3D-SIM microscopy we previously showed that REX1 is located at the edges of the Maurer's clefts 327 (11, 36, 37) . In this work, we showed that PTP5 also locates at the cleft periphery, partially 328 overlapping or intercalated with REX1 and PfEMP1. Collectively, these data points to a protein hub 329 that plays a role in the trafficking of PfEMP1 from the Maurer's clefts to the RBC membrane. 330
Interestingly two members of this peripherally located hub, REX1 and PF3D7_1353100, co-331 precipitate MAHRP2. MAHRP2 is located on parasite-derived structure called tethers that have 332 been proposed to link Maurer's clefts to the RBC membrane (13). 333
A second cluster comprises MAHRP1, VCAP1, GEXP10 and PIESP2. 3D-SIM microscopy 334 revealed that MAHRP1, VCAP1 and GEXP10 have an overlapping physical location in the central 335 14 region of the Maurer's clefts. Previous work has shown that MAHRP1 disruption prevents 336 trafficking of PfEMP1 to the Maurer's clefts (35), suggesting a possible role for this protein hub in 337 loading PfEMP1 into the Maurer's clefts. 338
We further characterised two proteins from this cluster, VCAP1 and GEXP10. These proteins show 339 sequence similarity (32% identity) and are the only members of the Hyp8 gene family of exported 340 Plasmodium proteins (47). They both contain a signal peptide and a PEXEL motif and have no 341 orthologues in other Plasmodium species. The two proteins were initially reported to be exported to 342 the RBC cytosol in gametocytes (27), but another report identified VCAP1 as a Maurer's cleft-343 associated protein in asexual stages (28). Yet another antibody-based study reported that VCAP1 344 and GEXP10 are located at the RBC surface in the asexual blood stage (29) and are implicated in 345 binding of infected RBCs to the chemokine CX3CL1. That study referred to them as CX3CL1-346
Binding Proteins 2 and -1 (CBP2 and CBP1, respectively). In our work, we show that both VCAP1 347 and GEXP10 are present at the Maurer's cleft with no detectable GFP tagged protein in the RBC 348 cytosol or at the RBC membrane. We therefore classify VCAP1 and GEXP10 as Maurer's cleft 349 resident proteins but it remains possible they also occupy other locations at levels below the limit of 350 detection in our analysis. 351
Previous attempts to genetically disrupt VCAP1 and GEXP10 were unsuccessful, suggesting these 352 may be essential (21, 28) . Using CRISPR-Cas9 and homology directed repair we were able to 353 successfully generate a VCAP1 parasite line but were unable to generate a GEXP10 knockout. 354
The inability to knock-out GEXP10 is consistent with data from the recent saturation-level 355 mutagenesis study (38) which showed that GEXP10 is indispensable, based on the lack of piggyBac 356 transposon insertion sites (Mean Insertion Score of 0.26). 357
The VCAP1 parasite line exhibited significant ultrastructural changes, with cleft fragmentation 358 and swelling. VCAP1 has two predicted transmembrane domains, as for the previously 359 characterised 2TM-MC Maurer's cleft protein family. The 2TM-MC proteins have been reported to 360 be oriented with the N-and C-terminal regions facing the RBC cytoplasm (48). If VCAP1 adopts an 361 equivalent orientation, its 26-amino acid loop (between the two transmembrane segments) would 362 face the Maurer's cleft lumen. It is possible that this loop sequence is involved in interactions that 363 stabilise the Maurer's clefts, and bring the two lamellae close together. Knock-out of VCAP1 also 364 leads to the formation of enlarged aberrant knobs and knob clusters, sometimes located at the ends 365 of membrane protrusions. Similarly, SEM imaging of the cytoplasmic face of infected RBC 366 membranes reveals doughnut-shaped knob structures that are much larger in the VCAP1 infected 367
RBCs than in the CS2 parent. 368
The aberrant knob and Maurer's cleft morphology is associated with a defect in the delivery of 369
PfEMP1 to the RBC membrane, as confirmed by trypsin cleavage assays and flow cytometry using 370 antibodies to the ectodomain of PfEMP1. As a consequence, the binding of the infected RBCs to 371 chondroitin sulphate-A was completely abrogated. 372
It is interesting to consider how the loss of a Maurer's cleft-resident protein could result in aberrant 373 knob morphology. While an earlier study using a chimeric KAHRP-GFP fusion (with a non-natural 374 signal sequence) suggested that KAHRP might be trafficked to the knobs via the Maurer's clefts 375 (49), more recent studies do not support this model. Thus, it seems unlikely that Maurer's cleft-376 located VCAP1 plays a direct role in KAHRP trafficking. We considered the possibility that there is 377 a small population of VCAP1 located at the RBC membrane, as previously proposed (29) which 378 may participate in knob assembly. However, we were unable to detect GFP-tagged VCAP1 at the 379 RBC membrane or in the RBC cytoplasm. 380
An alternative possibility is that VCAP1 is required for the trafficking of an unknown protein 381 required for knob assembly. A recent ultrastructural study visualised the knob complex as a spiral 382 structure connected by multiple links to the RBC membrane skeleton and coated by an electron-383 dense layer that likely represents KAHRP (50). An earlier cryo-electron tomography study revealed 384 branched actin filaments (each ~500 nm in length) that connect the Maurer's clefts to the RBC 385 membrane skeleton in the region of the knobs (12). Recent work from our laboratory suggests that 386 knobs are generated by the trafficking of individual KAHRP-containing modules to the RBC 387 16 membrane skeleton followed by assembly of KAHRP modules into ring-shaped complexes that sit 388 at the base of the physical knob structure (2). The composition of the spiral core remains unknown. 389
One possibility is that correctly formed Maurer's clefts may be needed for delivery of a knob 390 assembly factor. 391
The VCAP1 parasite line exhibited a growth advantage compared to wildtype CS2, perhaps 392 consistent with the general observation that knob-minus parasites outgrow knob-plus parasites in 393 culture. The abnormal knob morphology is associated with increased deformability, suggesting that 394 the reduced number of these aberrant knobs is unable to contribute the strain hardening effects 395 associated with wildtype knobs (51). Of interest, we found that VCAP1 infected RBCs are more 396 sensitive to osmotic changes, suggesting that the abnormal knobs weaken the membrane structure. 397
The current model for PfEMP1 trafficking suggests that it is trafficked across the RBC cytoplasm as 398 a chaperoned complex and then loaded into the membrane at the Maurer's clefts (52). Forward 399 trafficking delivers PfEMP1 into the RBC membrane bilayer from where it moves laterally to the 400 knobs to form the mature virulence complex (2). The exact mechanism of PfEMP1 unloading and 401 trafficking is not known but it has been speculated that PfEMP1-loaded vesicles bud from the 402 Maurer's clefts and traffic along remodelled actin filaments or tethers. In the VCAP1 parasite 403 infected RBCs we observe a dramatic fragmentation of the Maurer's clefts. We propose that this 404 compromises correct trafficking of both PfEMP1 and a knob assembly factor. VCAP1 is a basic 405 protein located in the central region of the Maurer's clefts. It is possible that VCAP1 interacts with 406 the acidic C-terminal segment of PfEMP1 and facilitates loading into the Maurer's cleft membrane. 407
It may then transfer PfEMP1 to REX1 (at the Maurer's cleft periphery) for onward delivery. Further 408 studies are required to fully elucidate the role of VCAP1 in virulence protein trafficking. 409
In summary, we have developed a novel method for enriching Maurer's clefts from late ring stage 410 P. falciparum-infected RBCs that avoids host cell membrane contamination. We identified a 411 number of novel Maurer's cleft proteins that expand the repertoire of resident proteins locating at 412 these structures. We characterised different protein hubs that may function in the trafficking of 413 PfEMP1 and determined their spatial organisation. In particular, we identified interacting proteins 414 located in the central region of the Maurer's clefts that may be involved in loading PfEMP1 into the 415 Maurer's cleft membrane. In the absence of one of these proteins, VCAP1, the Maurer's clefts swell 416 and fragment, the knobs enlarge and clump and PfEMP1 trafficking to the RBC membrane fails. 417
RBCs infected with VCAP1-disrupted parasites are more deformable, more sensitive to sorbitol 418 lysis and the parasites possess a growth advantage. A more detailed understanding of the steps in 419 the export pathway may reveal new strategies to target the parasite by blocking the delivery of 420
PfEMP1 to the infected RBC surface. 421 422
Materials and Methods 423
Plasmodium falciparum culture 424
Parasites were cultured as previously described (53) Percoll purification or magnetic separation (54, 55). Ring stage parasites were enriched by 430 treatment with 5% D-sorbitol (56). Knob positive parasites were enriched by flotation on 431 Gelofusine (Braun) as previously described for gelatin (57). Transfectants containing the pGLUX 432 plasmids were maintained in the presence of 5 nM WR99210 (Jacobus Pharmaceuticals). The 433 VCAP1 parasite line was maintained on 2 nM DSM1 (BEI Resources). 434 435
Plasmid construction and transfection 436
To create the GFP-tagged transfectant parasites used in this study, the full-length genes (minus the 437 stop codon) were amplified from 3D7 gDNA using primers incorporating XhoI and KpnI restriction 438 18 enzyme cleavage sites at the 5' and 3' ends of the gene (Table S9 ). Sequence verified DNA was 439 then directionally cloned into the XhoI and KpnI sites of the pGLUX vector. 440
To generate the VCAP1 knockout cell lines two regions of homology within the 5' and 3' of the 441 VCAP1 locus were PCR amplified using the primers as outlined in Table S9 . The HR1 was cloned 442 into the pUFTK plasmid containing a yeast dihydroorotate dehydrogenase cassette which confers 443 resistance to DSM1 using the AvrII and NcoI sites and HR2 was cloned into the SpeI and SacII site 444 of the plasmid. The guide RNA was selected using CHOP CHOP and cloned into the BtgZI 445 linearised pAIO-Cas9 vector containing a hDHFR selection cassette (58). Transfections were 446 performed as previously described (59). 447 448
Live cell and immunofluorescence microscopy 449
Infected red blood cell smears were fixed in an acetone and methanol solution at -20°C for 10 min. 450
Wells were marked with a hydrophobic PAP pen, then washed three times with PBS. Primary 451 antibodies were diluted in 3% (w/v) bovine serum albumin (BSA) and were added to the wells for 1 452 h at room temperature and subsequently washed three times with PBS. The primary antibodies used 453 in this study were: mouse anti-REX1 (1:1000, (20)), rabbit anti-REX1 (1:1000, (20)), mouse anti-454 GFP (1:300, Roche), rabbit anti-GFP (1:300, (60)), mouse anti-MAHRP1 (1:300, (23)), mAb anti-455 ATS (1:100, (19)), mouse anti-SBP1 (1:300, (18)), rabbit anti-HA (1:300, Sigma Aldrich). 456 Secondary anti-mouse or anti-rabbit AlexaFluor® 488, 568 or 647 antibodies (1:300 in 3% (w/v) 457 BSA, Life Technologies) were added to the wells for 1 h at room temperature, then wells were 458 washed 3 times with PBS. Each well was then treated with DAPI (4',6-diamidino-2-phenylindole) 459 and PPD antifade (p-phenylenediamine) prior to mounting and sealing. For live-cell fluorescence 460 microscopy, parasites were suspended in RPMI and mounted on a coverslip. Samples were imaged 461 on a DeltaVision Elite Restorative Widefield Deconvolution Imaging System (GE Healthcare). 462
Samples were excited with solid state illumination (Insight SSI, Lumencor). The following filter 463 sets with excitation and emission wavelengths were used: DAPI Ex390/18, Em435/48; FITC, 464 Ex475/28, Em523/26; TRITC, Ex542/27, Em594/45; Cy5 Ex 632/22, 676/34 nm. A 100x UPLS 465 Apo (Olympus, 1.4NA) oil immersion objective lens was used for imaging. For 3D Structured 466 Illumination microscopy (3D-SIM), the DeltaVision OMX V4 Blaze was used (GE Healthcare). 467
Samples were imaged using a 60X Olympus Plan APO N (1.42 NA) oil immersion lens. The 468 following laser emission and band pass filter sets were used: Ex488, Em528/48; Ex568, Em609/37 469 or Ex642, Em683/40 nm. Images were processed using the FIJI ImageJ software (61). 470
471

SDS-PAGE and immunoblotting of protein samples 472
For immunoblotting, samples were resuspended in Bolt™ LDS sample buffer and 50 mM 473 dithiothreitol (DTT) and separated on Bolt™ 4-12% Bis-Tris gel at 200V for 32 min. Separated 474 samples were transferred to a nitrocellulose membrane using an iBlot® gel transfer device. 475
Membranes were blocked in 3% (w/v) skim milk for 1 h at room temperature. The membranes were 476 then probed for 16 h at 4 °C with the following primary antibodies in 3% (w/v) skim milk in PBS: 477 mouse anti-GFP (1:1000, Roche), rabbit anti-SBP1 (1:1000, (18) ), mAb anti-ATS (1:100, (19) ), 478 mouse anti-REX1 (1:1000, (20) ), mouse anti-EXP1 (1:1000), rabbit anti-spectrin (1:1000, Sigma 479 Aldrich), mouse anti-MAHRP1 (1:1000, (23)), rabbit anti-GAPDH (1:1000), rabbit anti-HA 480
(1:1000, Sigma Aldrich). Membranes were washed 3 times in 0.05% (v/v) Tween-20 in PBS for 10 481 min. Secondary antibodies (anti-mouse or anti-rabbit) conjugated to horseradish peroxidase (HRP, 482 Promega) were diluted 1:25,000 in 3% (w/v) skim milk in PBS and were incubated with 483 membranes for 1 h at room temperature. Membranes were again washed 3 times in 0.05% (v/v) 484
Tween-20 in PBS, then once in PBS before being incubated with Clarity™ ECL reagents (Bio-Rad) 485 and visualised on a ChemiDoc imaging system (Bio-Rad). 486 487
Enrichment of Maurer's clefts 488
Parasites were synchronised to a 4 h window by Percoll purification followed by sorbitol lysis. At 489 14-18 h post-invasion, parasites (~15% parasitaemia) were harvested and washed in PBS. Infected 490 20 red blood cells were lysed on ice with chilled hypotonic buffer (1 mM HEPES/NaOH, Roche 491 cOmplete EDTA-free protease inhibitor, pH 7.4). The lysed infected red blood cell solution was 492 passaged through a 27-gauge needle 10 times and was then made isotonic by the addition of 4X 493 assay buffer 200mM NaCl, 8 mM EDTA (pH 7.4) . The solution was 494 centrifuged at 2500 g for 10 min at 4 °C, the supernatant was collected and centrifuged again at 495 2500 g for 10 min at 4 °C. The supernatant (containing the Maurer's clefts) was then pre-cleared 496 with Pierce™ Protein A agarose beads (Thermo Scientific) for 30 min at 4 °C on a mixing wheel. 497
The Protein A agarose beads were pelleted by centrifugation and the supernatant was incubated 498 with GFP-Trap® agarose beads (Chromotek) for 4 h at 4 °C on a mixing wheel. The beads were 499 then collected and used for downstream applications. 500 501
Co-IP with GFP-Trap agarose beads 502
Parasite-infected RBCs were purified using a VarioMACS™ (Miltenyi Biotec) magnet or by 503 floatation in 70% (v/v) Gelofusine® (Braun) in PBS. The infected RBCs were washed in RPMI and 504 then solubilised on ice for 30 min in 10 times pellet volumes of IP buffer (1% (v/v) Triton X-100, 505 150 mM NaCl, 50 mM Tris, 8 mM EDTA) with Complete™ protease inhibitor cocktail (Roche). 506
The Triton X-100-insoluble material was pelleted twice by centrifugation (10 min at 16,000 g). The 507 supernatant was pre-cleared with Pierce™ Protein A agarose beads (Thermo Scientific) for 1 h at 4 508 °C on a mixing wheel. The Protein A beads were pelleted and an aliquot of the supernatant was 509 taken as the input fraction. The remainder of the supernatant was incubated with washed GFP-Trap 510 agarose beads (Chromotek) for 16 h at 4 °C. The GFP-Trap beads were then washed 5 times in IP 511 buffer. 512 513
Mass spectrometric analysis of Maurer's clefts and co-IPs 514
Agarose beads were washed twice in 1 mM Tris-HCl prior to elution of bound proteins. Samples 515 were prepared for mass spectrometric analysis as previously described (31). Briefly, proteins were 516 21 eluted from GFP-Trap beads by the addition of 20% (v/v) trifluoroethanol in formic acid (0.1%, pH 517 2.4) and were incubated at 50°C for 5 min. The eluate was reduced with 5 mM TCEP (Thermo 518
Fischer Scientific) and neutralised with TEAB (tetraethylammonium bromide). Samples were 519 digested with trypsin (Sigma) overnight at 37 °C. Ibidi µ-Slide 0.2 channel slides were incubated with 100 µl chondroitin sulfate A (100 µg/ml, 533 Sigma) in 1% (w/v) BSA in PBS overnight at 37˚C. Channels were blocked with 1% (w/v) BSA in 534 PBS for 1 h at room temperature then gently flushed with warm bicarbonate-free RPMI 1640 535 (Invitrogen). Mid-trophozoite stage cultures were diluted to 3% parasitemia and 1% haematocrit in 536 bicarbonate-free RPMI 1640 and pulled through the channel at 100 µl/min for 10 min at 37˚C. 537
Unbound cells were washed out of the channel at 100 µl/min for 10 min at 37˚C. Adherent cells 538 were counted at 10 points along the axis of the channel. 539 540 VAR2CSA ectodomain labelling and analysis via flow cytometry 541 22 Mid-trophozoite cultures were diluted to 3% parasitemia, 0.4% hematocrit and plated into a 96 well 542 plate. Cells were washed 3 times in 1% (w/v) BSA in PBS and incubated with a rabbit polyclonal 543 anti-VAR2CSA for 30 min at 37˚C (R1945 1:50, Elliott et al., 2005) or a 1% (w/v) BSA in PBS 544 control. Cells were washed in 1% BSA/PBS between all subsequent incubations and all antibodies 545 were diluted in 1% BSA/PBS. Cells were incubated with mouse anti-rabbit IgG (Dako; 1:100) for 546 30 min at 37˚C, then mouse anti-GFP (Alexa Fluor-488) under the same conditions. Following 547 tertiary labelling, cells were washed 3 times in 1% (w/v) BSA in PBS. Nuclei were stained with 548 SYTO61 as described previously (Klonis et al., 2011) and analysed via flow cytometer (BD 549 FACSCanto II). SYTO61 positive cells were gated and the Alexa Fluor-488 fluorescence intensity 550 measured. The results are displayed as the percentage of fluorescence relative to wild type controls. 551
552
Trypsin cleavage of surface exposed PfEMP1 553
Late stage infected RBCs were purified and incubated with 20 volumes of 1 mg/ml TPCK-treated 554 trypsin in PBS (Sigma) or trypsin and soybean trypsin inhibitor (5 mg/ml, Sigma) at 37˚C for 1 h. 555
Trypsin activity was quenched with a 15 min incubation with trypsin inhibitor at room temperature 556 for 15 min. Cells were subsequently solubilised in 1% Triton X-100 in PBS containing 1x cOmplete 557 protease inhibitor (Roche) and incubated on ice for 20 min. The sample was centrifuged at 16,000 x 558 g at 4C for 10 min and the resulting pellet washed in the triton solution 2 additional times. The 559 resulting triton-insoluble pellet was solubilized in 2% SDS in PBS and mixed on a rotating wheel 560 for 40 min. This SDS-soluble fraction was then separated by SDS-PAGE and transferred to a 561 nitrocellulose membrane for western blotting. 562 563
Parasite growth assay 564
Parental CS2 and ∆VCAP1 cell lines were synchronised to a 2 h window and diluted to 1.5% late 565 stage parasitemia. Every 48 h infected red blood cells were taken from culture and stained with 566 SYTO-61 nuclear stain and parasitemia was calculated by flow cytometry as previously described 567 23 (Klonis et al., 2011) . The cultures were then diluted by the same dilution factor. Parasitaemia was 568 recorded over 4 cycles and normalised to the parental CS2 line. 569 570
Sorbitol sensitivity assay 571
Mid-trophozoite infected red blood cells at 2-5% parasitemia were incubated at 37˚C with one of 12 572 solutions between 0.1% (w/v) and 5.5% (w/v) D-sorbitol. Parasitemia was measured via flow 573 cytometry following incubation with nuclear stain SYTO-61 and 30,000-50,000 events recorded per 574 well as previously described (Klonis et al., 2011) . Parasitemia was normalised to an internal RPMI 575 control for each cell. This data was then used to calculate the IC50 values for each separate 576 experiment. The IC50 values from each experiment are plotted. 577 578
Microbead filtration 579
Spleen mimic filtration was performed to assess the deformability properties of parasite infected 580 RBC (63) . Synchronous parasites at 22 h post-invasion were prepared at 6% parasitemia and 1% 581 hematocrit in 1% (w/v) AlbuMAX II in 1X PBS and flowed through the microbead bed using a 582 syringe pump at a flow rate of 60mL/min. The data presented is the percentage of parasites present 583 in the flow through relative to starting parasitemia. The mean and standard error are plotted, from 3 584 separate experiments. A Students t-test was used to evaluate statistical significance. 585 586
Membrane shearing 587
Glass coverslips were cleaned with acetone and 50% methanol prior to treatment with 3-588 aminopropyl triethoxysilane (APTES), bis-sulfosuccimidyl suberate and addition of the ligand 589 erythroagglutinating phytohemagglutinin (PHAE) as previously described (64). Infected RBCs 590 were immobilised on the functionalised glass slides, then sheared by applying a hypotonic buffer (5 591 mM Na 2 HPO 4 /NaH 2 PO 4 , 10 mM NaCl, pH 8) from a 30 mL syringe (23-G needle) at an angle of 592 ~20° (65). The membrane disks were placed in PBS prior to down-stream imaging. 593 24 594 595 596
Scanning Electron Microscopy 597
Whole infected RBC cell samples bound to glass coverslips were immersed in 0.05% 598 glutaraldehyde in PBS for 20 minutes prior to fixation in 2.5% glutaraldehyde for 2 h at room 599 temperature. Sheared membranes were prepared for scanning electron microscopy as previously 600 described (2). In brief, sheared cells were fixed immediately after lysis with 2.5% glutaraldehyde in 601 PBS for 2 h at room temperature. Both whole and sheared cell samples were then washed 602 thoroughly with deionised water and dehydrated via sequential 5 min incubations in 20%, 50%, 603 
